Medplus Health Services Limited has informed the Exchange about Transcript
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
MedPlus reported Q4 FY26 consolidated revenue of INR 18,644 million with operating EBITDA of INR 1,076 million (5.8%). The company expanded its store network to 5,330 stores (net addition of 618 in FY26) and plans to open 800 net new stores in FY27 including franchisee outlets. Private label currently constitutes 22% of revenues (11.4% pharma, 10.6% non-pharma). Store-level EBITDA for mature stores (>12 months) stood at 13.1%, and mature store SSSG was 17.8% for the quarter. Management confirmed its private label growth guidance remains intact and expects to maintain current profitability levels before growing further. The company reiterated its SSSG annual guidance of 9-10% going forward. Franchisee model is profitable from day one with ~9.5-10% store-level EBITDA retained by the company. Private label non-pharma margins are 23-25% (vs 9-10% for branded non-pharma). The company is a zero-debt firm with all debt being lease-related accounting.
MedPlus demonstrates strong operational metrics with improving store-level margins and accelerating store expansion through both company-owned and franchisee models. The franchisee model provides capital-light growth while maintaining profitability. Focus on private label expansion, especially in non-pharma, should be accretive to margins over time.